IBJNews

Lilly’s Bydureon wins backing of European drug panel

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. and Amylin Pharmaceuticals Inc., rebuffed twice in their bid for U.S. approval of a weekly diabetes drug, won the backing of European Union regulators for the product.

Bydureon should be approved by the European Commission for Type 2 diabetes in adults, the London-based European Medicines Agency said Friday in a statement, following a 183-day review by its Committee for Medicinal Products for Human Use.

The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.

Bydureon is a longer-acting version of the twice-daily diabetes injection Byetta sold by San Diego-based Amylin and Indianapolis-based Lilly. A weekly drug would be more convenient for patients and help the company compete with Novo Nordisk A/S, the world’s biggest insulin maker.

Amylin lost 46 percent of its market value Oct. 20 after saying the U.S. Food and Drug Administration wanted a study assessing the drug’s heart risks. The shares rose $2.24, or 20 percent, to $13.50 each overnight in premarket trading.

Byetta, a synthetic version of a substance found in the saliva of the Gila monster, stimulates pancreas cells to produce the hormone insulin when blood sugar is high. Novo Nordisk’s Victoza, which works in a similar way, can be taken once a day instead of twice. Victoza had worldwide sales of $450 million last year, Novo Nordisk said Feb. 2.

Lilly markets Byetta outside the U.S. and co-markets it with Amylin in the U.S. The drug was developed by Amylin, and the technology enabling it to be used in a longer-acting form was developed by Waltham, Mass.-based Alkermes Inc. Alkermes will receive royalties of about 8 percent on Bydureon sales.

Amylin and its marketing partners plan to submit a response to the FDA in the second half of 2011, the companies said in a March 3 statement. Shares in Amylin and Alkermes plunged that same day after a study showed Bydureon didn’t control the disease better than Victoza.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT